INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Inhibitor - Estudio Retrospectivo De Casos Clinicos De Pacientes Con Carcinoma De Celulas Renales Y Con Linforma De Celulas Del Manto Tratados Con Temsirolimus
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Contacts et emplacements
Lieux d'étude
-
-
-
A Coruña, Espagne, 15006
- Complexo Hospitalario Universitario A Coruña
-
Avila, Espagne, 05004
- Complejo AAsistencial de Avilla
-
Barcelona, Espagne, 08035
- Hospital Vall d'hebrón
-
Barcelona, Espagne, 08025
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Espagne, 8940
- Hospital Del Mar
-
La Coruña, Espagne, 15006
- Complexo Hospitalario Universitario A Coruña. Hospital Teresa Herrera
-
Madrid, Espagne, 28046
- Hospital Universitario La Paz
-
Madrid, Espagne, 28007
- Hospital General Universitario Gregorio Marañón
-
Madrid, Espagne, 28033
- MD Anderson Cancer Center
-
Madrid, Espagne, 28050
- Hospital de Madrid Norte - Sanchinarro
-
-
Asturias
-
Oviedo, Asturias, Espagne, 33006
- Hospital Universitario Central de Asturias
-
-
Gijon
-
Cabueñes, Gijon, Espagne, 33394
- Hospital de Cabueñes
-
-
La Coruña
-
Santiago de Compostela, La Coruña, Espagne, 15706
- Hospital Clinico Universitario
-
-
Las Palmas
-
Las Palmas de Gran Canaria, Las Palmas, Espagne, 35016
- Complejo Hospitalario Materno-Infantil Insular de Las Palmas
-
-
Navarra
-
Pamplona, Navarra, Espagne, 31008
- Hospital de Navarra
-
-
Valencia
-
Castellon, Valencia, Espagne, 12002
- Hospital Provincial de Castellon
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
Exclusion Criteria:
Patients that do not have a minimum (pre-specified) of data in their clinical record.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Patients that received treatment with Temsirolimus
Patients with Renal Cell Carcinoma or Mantle Cell Lymphoma that have been treated with Temsirolimus as per clinical practice.
|
There is not any intervention in this study.
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free Survival (PFS)
Délai: From initiation of treatment up to disease progression (up to 80 months)
|
Progression-free survival: interval between start of treatment to first day when progressive disease (PD) was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) for participants with RCC and Cheson criteria for participants with MCL, or death due to any cause.
RECIST criteria: at least 20% increase in sum of diameters of target lesions, taking as reference the smallest sum.
In addition to relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm).
Appearance of one or more new lesions also considered progression.
Cheson criteria: appearance of any new sites of lymphoma OR at least 50% increase in product of longest perpendicular dimensions of any previously identified lymph node mass (LNM) OR at least 50% increase in longest dimension of any previously identified LNM greater than 1 cm in longest transverse dimension OR at least 50% increase in size of any previously involved site of lymphoma.
|
From initiation of treatment up to disease progression (up to 80 months)
|
|
Percentage of Participants With Objective Response
Délai: From initiation of treatment up to disease progression (up to 80 months)
|
Objective response: percentage of participants who achieved complete remission (CR) or partial response (PR).
RECIST criteria was used for participants with RCC and Cheson criteria for participants with MCL.
RECIST criteria (CR: disappearance of all target lesions, any pathological lymph nodes(target or non-target) reduced in short axis to <10 mm, PR: at least 30% decrease in sum of diameters of target lesions).
Cheson criteria (CR: all lymph node masses regressed to normal size, each lymph node mass that was >1.5 cm in longest transverse dimension regressed to <=1.5 cm, lymph node mass that was 1.1-1.5 cm regressed to <=1 cm, complete disappearance of all radiographic evidence of disease, PR: at least 50% decrease in sum of products of the longest perpendicular dimensions of the previously identified dominant lymph node masses, no increase in size of other lymph nodes.)
|
From initiation of treatment up to disease progression (up to 80 months)
|
|
Duration of Response (DOR)
Délai: From initiation of treatment up to disease progression (up to 80 months)
|
Duration of response (DOR) was defined as the interval from the date the response was documented to the first date that progression of disease (PD) was observed in participants with PR or CR.
RECIST criteria was used for participants with RCC and Cheson criteria for participants with MCL.
PD, CR and PR are defined in primary outcome 1 and 2.
|
From initiation of treatment up to disease progression (up to 80 months)
|
|
Overall Survival (OS)
Délai: From initiation of treatment untill death (up to 80 months)
|
Overall survival (OS) was defined as the interval from the day of the start of the treatment to death, or censored to the last date when the participant was identified to be alive.
|
From initiation of treatment untill death (up to 80 months)
|
|
Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Délai: Baseline to the 28 calendar days after the last administration of study drug (upto 80 months)
|
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Treatment-emergent events were between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
AEs included both SAEs and non-serious adverse events (Non-SAEs).
|
Baseline to the 28 calendar days after the last administration of study drug (upto 80 months)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies du système immunitaire
- Tumeurs par type histologique
- Tumeurs
- Troubles lymphoprolifératifs
- Maladies lymphatiques
- Troubles immunoprolifératifs
- Lymphome non hodgkinien
- Tumeurs urologiques
- Tumeurs urogénitales
- Tumeurs par site
- Maladies rénales
- Maladies urologiques
- Adénocarcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs rénales
- Lymphome
- Carcinome à cellules rénales
- Carcinome
- Lymphome à cellules du manteau
- Effets physiologiques des médicaments
- Agents anti-infectieux
- Agents antinéoplasiques
- Agents immunosuppresseurs
- Facteurs immunologiques
- Agents antibactériens
- Antibiotiques, Antinéoplasiques
- Agents antifongiques
- Sirolimus
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- B1771017
- INHIBITOR (Autre identifiant: Alias Study Number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .